Although shares have retreated from their all-time high, those who bought shares one year ago are still looking at growth in ...

Tempus AI achieves strong revenue growth and beats expectations, but ongoing losses and execution risks temper enthusiasm.

Tempus AI TEM stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 66 to 78. Please ...

In conjunction with its better-than-expected sales growth in the second quarter, Tempus AI raised its sales outlook for this year. The company now expects full-year revenue to come in at roughly $1.26 ...

Tempus AI (TEM) has posted an impressive price move of 21% over the last week, likely influenced by a blend of recent developments. The company announced significant revenue growth in its second ...

Tempus AI offers a strong business model with AI-driven genomic data, resilient demand, and significant growth prospects. Click here to read why TEM is a Hold.

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Tempus AI, Inc. TEM is scheduled to report second-quarter 2025 results on Aug. 8. In the last reported quarter, the company’s adjusted loss of 24 cents was narrower than the Zacks Consensus ...

Shares of Tempus AI climbed after the company narrowed its net loss and logged higher-than-expected revenue in the second quarter, boosted by what Chief Executive Eric Lefkofsky called a significant ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...